Compare GSK plc (GSK) vs Xpeng Inc - ADR (XPEV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs Xpeng Inc - ADR — how do they compare? GSK plc trades at $52.65 (market cap $101.34B), while Xpeng Inc - ADR trades at $14.16 (market cap $12.82B). The key difference: GSK plc is far larger — about 7.9× Xpeng Inc - ADR's market cap, and GSK plc pays a 3.49% dividend while Xpeng Inc - ADR pays none. Which is the better fit depends on your goals.
| GSK | XPEV | |
|---|---|---|
Market Cap | $101.34B | $12.82B |
Sector | Health | Consumer Cyclical |
52-Week High | $61.18 | $28.07 |
52-Week Low | $36.20 | $12.09 |
Enterprise Value | $121.95B | $14.93B |
Dividend Yield | 3.49% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK trades at $52.64, up 2.7% on the day, with a bearish technical signal despite recent earnings beats. The company reported Q1 2026 EPS of $1.24, beating estimates of $1.16, and maintains strong profitability with a 17.78% net income margin. Positive clinical trial results for Jemperli in rectal cancer and FDA approval for Utebzi highlight pipeline strength, while a pending acquisition of Nuvalent, Inc. signals strategic expansion.
GSK offers value with a P/E of 13.71 and stable cash flows, but faces risks from clinical setbacks, as seen in the terminated Alector partnership. Analyst sentiment is mixed with 31% buy ratings, reflecting cautious optimism amid competitive and regulatory pressures. The stock's outlook hinges on execution of growth initiatives and pipeline developments.
XPeng (XPEV) trades at $14.255, up 6.7% on the day, showing bullish technical momentum. The company reported $76.72B revenue for 2025 with improving net margins (-1.49% vs -14.17% in 2024), though it remains unprofitable. Recent news highlights strong Q2 2026 deliveries of 103,295 vehicles and expansion into autonomous driving and robotics, positioning it as a physical AI leader. Analyst sentiment is predominantly bullish with 64.7% buy ratings.
The outlook is cautiously optimistic with revenue growth and margin improvement as key catalysts, but risks include persistent losses, intense EV competition, and macroeconomic pressures. Institutional support and new model launches provide upside potential, yet profitability remains the critical hurdle for sustained shareholder value.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About Xpeng Inc - ADR
Founded in 2015, XPeng is a leading Chinese smart electric vehicle, or EV, company that designs, develops, manufactures and markets EVs in China. Its products primarily target the growing base of technology-savvy middle-class consumers in the midrange to high-end segment in China's passenger vehicle market. The company sold over 98,000 EVs in 2021, accounting for about 3% of China's passenger new energy vehicle market. It is also a leader in autonomous driving technology.
Read more on XPEV →
